Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Targeted therapy controls but does not cure; how to stop it safely is unknown.
Neurodegenerative disease appears years later and has no proven treatment.
Reactivation affects a third or more of children despite twelve months of therapy.
Adults are treated by extrapolation from paediatric protocols.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
12 vs 6 months of vinblastine-prednisone: 5-year reactivation 37% vs 54% in risk-organ-negative disease; methotrexate added no benefit.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.